Carbon Monoxide Release for Compartment Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute limb compartment syndrome (CS) are limited by the need for immediate surgical intervention to prevent permanent tissue damage, as delays can lead to irreversible muscle and nerve damage, with no effective preventive methods available.
Innovation Solution
Administration of carbon monoxide (CO) through CO-releasing molecules (CORMs), such as CORM-3, to attenuate and treat compartment syndrome by reducing compartment pressure and preserving muscle tissue function, allowing for a delayed surgical intervention without increasing carboxyhemoglobin levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate surgical fasciotomy is performed to treat compartment syndrome, then permanent tissue damage is prevented, but surgical intervention complexity and patient morbidity increase
Solution Approach 1:
The patent applies preliminary action by administering carbon monoxide (CO) therapy before surgical fasciotomy to pre-treat the ischemic tissue and reduce the severity of compartment syndrome. This preliminary pharmacological intervention protects tissues from irreversible damage, potentially allowing for less aggressive surgical decompression while maintaining patient outcomes.
Solution Approach 2:
Carbon monoxide acts as an intermediary substance between the compressed tissue and the surgical intervention. The CO molecules mediate the protective effect by binding to heme proteins and activating protective signaling pathways, thereby reducing tissue vulnerability to ischemic injury without requiring immediate surgical decompression.
2Device complexity
If delayed surgical intervention is performed to reduce morbidity, then permanent tissue damage occurs, but patient suffering increases
Solution Approach 1:
By administering CO therapy in advance of surgical intervention, the patent creates a protective window that allows delayed surgery without permanent tissue damage. The preliminary CO treatment activates cellular defense mechanisms that protect against ischemic injury, effectively extending the safe time window for surgical decompression.
Solution Approach 2:
Carbon monoxide provides beforehand cushioning by pre-conditioning the tissue to withstand ischemic stress. The CO molecules accumulate in tissues and activate protective pathways before the surgical intervention occurs, cushioning the tissue against the harmful effects of delayed decompression and preventing irreversible damage.
3Reliability
If inhaled carbon monoxide is administered to treat compartment syndrome, then microvascular perfusion is protected, but carboxyhemoglobin levels increase causing potential harm
Solution Approach 1:
The patent extracts the therapeutic benefit of carbon monoxide (microvascular protection) while removing the harmful aspect (carboxyhemoglobin formation). This is achieved by using alternative administration routes such as topical application, intravenous infusion of CO-releasing compounds, or direct tissue injection, which deliver CO to the affected compartment without significant systemic absorption and carboxyhemoglobin formation.
Solution Approach 2:
CO-releasing molecules serve as intermediaries that deliver carbon monoxide directly to the affected tissue without requiring inhalation. These molecules release CO locally at the site of compartment syndrome, providing microvascular protection while avoiding the systemic circulation and carboxyhemoglobin formation associated with inhaled CO administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of CO-releasing molecules effectively reduces tissue injury and inflammation, extending the surgical window for fasciotomy and minimizing morbidity associated with CS, thereby preventing irreversible damage to muscles and nerves.
Implementation Method 1
it is now recognized that inhalation of low levels of carbon monoxide have anti-inflammatory effects in some models and to offer protection to microvascular perfusion
Implementation Method 2
offer protection to microvascular perfusion
Implementation Method 3
Transitional metal carbonyls, CO-releasing molecules (CO-RMs) have been used to deliver CO in a controlled manner without significantly altering COHb
Implementation Method 4
liberation of CO produced vasorelaxant effects, decreased myocardial ischemia/reperfusion damage, and reduced inflammatory response
Data Source
AI summary
The present invention relates to a method of treating or preventing compartment syndrome in a patient. According to the invention, the method includes: (a) identifying a patient suffering from compartment syndrome; and (b) administering to the patient a therapeutically effective amount of a carbon monoxide (CO).